
|Articles|January 5, 2022
Clinical Pearl of the Day: Gastroparesis
Author(s)Saro Arakelians, PharmD
In patients with gastroparesis, the stomach's motility is slowed down or doesn't work at all, preventing proper emptying.
Advertisement
Clinical Pearl of the Day: Gastroparesis
Gastroparesis is a condition that affects the normal spontaneous movement of the muscles (motility) in the stomach.
Insight:
- The strong muscular contractions propel food through the digestive tract. But in patients with gastroparesis, the stomach's motility is slowed down or doesn't work at all, preventing proper emptying.
- Causes of gastroparesis is usually unknown. Sometimes it's a complication of diabetes and some people develop gastroparesis after surgery.
- Certain medications, such as opioid pain relievers, some antidepressants, high blood pressure medications, and allergy medications can lead to slow gastric emptying and cause similar symptoms.
- Symptoms may include vomiting, nausea, abdominal bloating, abdominal pain, a feeling of fullness, acid reflux, lack of appetite, and weight loss.
- Risk factors may include diabetes, abdominal surgery, scleroderma, and hypothyroidism.
- Diagnosis may include scintigraphy, and breath tests.
- Treatment may include changes in the diet, drinking extra fluids, taking medications that stimulate the stomach muscles, such as metoclopramide (Reglan), and erythromycin. Also, the patients can be prescribed medications for nausea and vomiting, including diphenhydramine (Benadryl), ondansetron (Zofran), and prochlorperazine (Compro).
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
IRAKLIA Trial Shows Body Weight Doesn’t Alter Outcomes With On-Body Injector Isatuximab
3
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
4
FDA Approves Lerodalcibep for Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia
5

















































































































































































































